Pilot study of p62 DNA vaccine in dogs with mammary tumors

Vladimir Gabai; Franco M. Venanzi; Elena Bagashova; Oksana Rud; Francesca Mariotti; Cecilia Vullo; Giuseppe Catone; Michael Y. Sherman; Antonio Concetti; Andrey Chursov; Anastasia Latanova; Vita Shcherbinina; Victor Shifrin; Alexander Shneider

doi:10.18632/oncotarget.2516

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Pilot study of p62 DNA vaccine in dogs with mammary tumors

Vladimir Gabai _, Franco M. Venanzi, Elena Bagashova, Oksana Rud, Francesca Mariotti, Cecilia Vullo, Giuseppe Catone, Michael Y. Sherman, Antonio Concetti, Andrey Chursov, Anastasia Latanova, Vita Shcherbinina, Victor Shifrin and Alexander Shneider

PDF | HTML | How to cite

Oncotarget. 2014; 5:12803-12810. https://doi.org/10.18632/oncotarget.2516

Metrics: PDF 2449 views | HTML 3239 views | ?

Abstract

Vladimir Gabai1,*, Franco M. Venanzi2,*, Elena Bagashova3, Oksana Rud3, Francesca Mariotti2, Cecilia Vullo2, Giuseppe Catone2, Michael Y. Sherman4, Antonio Concetti2, Andrey Chursov1, Anastasia Latanova1,5, Vita Shcherbinina1,5 , Victor Shifrin1,* and Alexander Shneider1,5

1 CureLab Oncology Inc, Needham MA, USA

2 School of Biosciences and Veterinary Medicine University of Camerino, Camerino (MC) Italy

3 Center of Modern Veterinary Medicine, Kiev, Ukraine

4 Department Biochemistry, Boston University School of Medicine, Boston MA, USA

5 CL Oncology Moscow, Russia

* joint 1st authorship

Correspondence:

Victor Shifrin, email:

Alexander Shneider, email:

Keywords: cancer immunotherapy, vaccine, breast carcinoma, neoadjuvant, p62, canine

Received: September 03, 2014 Accepted: September 24, 2014 Published: September 25, 2014

Abstract

Our previous data demonstrated profound anti-tumor and anti-metastatic effects of p62 (sqstm1) DNA vaccine in rodents with various types of transplantable tumors. Testing anti-cancer medicine in dogs as an intermediary step of translational research program provides two major benefits. First, clinical data collected in target animals is required for FDA/USDA approval as a veterinary anti-cancer drug or vaccine. It is noteworthy that the veterinary community is in need of novel medicine for the prevention and treatment of canine and feline cancers. The second more important benefit of testing anti-cancer vaccines in dogs is that spontaneous tumors in dogs may provide invaluable information for human trials. Here, we evaluated the effect(s) of p62 DNA vaccine on mammary tumors of dogs. We found that p62 DNA vaccine administered i.m. decreased or stabilized growth of locally advanced lesions in absence of its overall toxic effects. The observed antitumor activity was associated with lymphocyte infiltration and tumor encapsulation via fibrotic reaction. This data justifies both human clinical trials and veterinary application of p62 DNA vaccine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2516

Publication Alerts

Research Papers:

Pilot study of p62 DNA vaccine in dogs with mammary tumors

Abstract